Best Life Sciences Companies in Wilmington, United States
The 82 best Life Sciences companies in Wilmington, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Incyte.
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Wilmington
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Incyte Developer of small molecules for the treatment of different cancer and skin diseases | $750M | 151 mo ago | 1,387 | Herve Hoppenot Chairman and CEO | Public | 7,097 patents Small-molecule kinase inhibitors and formulations for JAK/TYK, PI3K, and related therapies | 2 awards |
| 2 | NiKang Therapeutics Developer of therapeutics for the treatment of cancer | $260M | 60 mo ago | 24 | Zhenhai Gao Co-Founder & CEO | Series C | 203 patents Design of heterocyclic small‑molecule inhibitors for oncology targets (HIF‑2α, KRAS G12D, CDK2, SH2). | — |
| 3 | Novel Therapeutic Technologies Topical drug delivery technology | $75M | 174 mo ago | — | Zacki Turkeltaub President & CEO | Series D | — | — |
| 4 | NRx 🦄 Developer of therapeutics for COVID-19 and neurological disorders | $55M | 52 mo ago | 22 | Daniel Javitt Co-Founder | Public | — | — |
| 5 | Ayala Pharma Developer of small molecule-based therapeutics for cancer treatment | $51M | 64 mo ago | 21 | — | Public | — | — |
| 6 | NeuroTherm Minimally invasive solutions for chronic pain including radiofrequency catheters and abation systems | $50M | 183 mo ago | 127 | — | Acquired | 29 patents Neuromodulation devices for diagnosing/treating neural disorders and spinal disc therapy | — |
| 7 | DUSA Pharma Dermatology products for actinic keratosis and acne. | $43M | 315 mo ago | 177 | Robert Doman CEO & President | Acquired | — | — |
| 8 | Converge Developer of GenAI computational tools for drug discovery and manufacturing | $30M | 8 mo ago | — | Dov Gertz Co-Founder & CEO | Series A | — | — |
| 9 | Topography Health The company provides a full-stack clinical trials platform for community physicians | $28M | 53 mo ago | 12 | Andrew Kirchner Co-Founder | Series A | — | — |
| 10 | iBio Developer of biologics products by using transient gene expression | $18M | 13 mo ago | 23 23 → 57 (+148%) | — | Public | 135 patents Therapeutic antibody engineering with conditional activation and masked antibody technologies | — |
| 11 | Ahura Scientific Developer of optical systems to identify solid and liquid chemicals | $17M | 231 mo ago | 120 | — | Acquired | — | — |
| 12 | dermaliq Therapeutics Developer of therapeutics for dermatological indicatications | $15M | 53 mo ago | 4 | Oliver Schluter Co-Founder & CFO | Series A | — | — |
| 13 | Micro Medical Solutions Developer of a device for CLI and PAD patients to prevent amputation | $13M | 7 mo ago | 13 | Gregory Sullivan Co-Founder & CEO | Series B | — | — |
| 14 | CuraVac Biotech pioneering targeted active immunotherapies for autoimmune diseases, aiming for long-term immunity | $8M | — | 6 | — | Funding Raised | 17 patents Peptide-based therapeutic vaccines targeting autoimmune myasthenia gravis | — |
| 15 | Leucine Developer of AI-powered software for pharmaceutical manufacturing, quality, and laboratory | $8M | 32 mo ago | 41 | Vivek Gera Co-Founder & CEO | Series A | — | — |
| 16 | RxWare Provider of solutions for managing manufacturing operations in manufacturing industries | $7M | 10 mo ago | 30 | — | Series A | — | — |
| 17 | Carecubes Provider of mobile isolation units for infection control in hospitals | $6M | 3 mo ago | 4 | Saul Griffith Co-Founder | Series A | 9 patents Infection-control isolation rooms and units for medical facilities | — |
| 18 | CureDM Developing new therapies based on HIP for diabetes | $5M | 202 mo ago | 3 | — | Acquired | 64 patents Therapeutic peptides for pancreatic islet regeneration and diabetes treatment | — |
| 19 | Sensible Biotechnologies Developer of mRNA technology for therapeutics and vaccines | $4M | 40 mo ago | 12 | Miroslav Gasparek Co-Founder & CEO | Seed | — | — |
| 20 | Electronic Lab Logs Provider of cloud-based electronic laboratory log management platform | $4M | 23 mo ago | 6 | Daniel Summers Founder & CEO | Seed | — | — |
| 21 | NuCalm Neuroscience-backed app for stress relief, sleep, focus, and recovery | $2M | 102 mo ago | 12 | — | Seed | — | — |
| 22 | Notitia Developer of therapeutic solutions for the treatment of diabetes & infectious diseases | $2M | 66 mo ago | — | Liping Zhao Co-Founder | Seed | — | — |
| 23 | Halo Columns Developer of high-performance liquid chromatography columns for researchers | $873K | 35 mo ago | 46 | — | Funding Raised | — | — |
| 24 | Von Vascular Developer of medical devices for thrombectomy procedures | $693K | 14 mo ago | — | Manning Hanser CEO | Funding Raised | — | — |
| 25 | Cellergy Pharma Developer of immunotherapeutics to treat allergic diseases | $600K | 16 mo ago | — | Mark Ma Co-Founder | Funding Raised | — | — |
| 26 | CardioDiagnostics Remote monitoring and transmission of vital cardiac information | $540K | 81 mo ago | 35 | — | Seed | — | 1 launch |
| 27 | BioCurie AI-based software for cell and gene therapy | $500K | 12 mo ago | — | Irene Rombel Co-Founder & CEO | Seed | 7 patents AI‑enabled data‑driven development and manufacturing of biopharmaceutical processes | — |
| 28 | Evidose Platform providing high-quality and scientifically robust data for the supplement and pharma industries | $500K | 30 mo ago | — | Anna Litwinska Co-Founder & CEO | Seed | — | — |
| 29 | Mogling Bio Developer of cell-based therapeutics for blood cancer | $300K | 20 mo ago | — | Hartmut Geiger Co-Founder | Seed | — | — |
| 30 | Microgenesis Provider of smart solutions for fertility & pregnancyhealth monitoring | $250K | 72 mo ago | 15 | Gabriela Gutierrez Founder | Seed | 14 patents Diagnostic and therapeutic assessment of reproductive inflammatory conditions for fertility | — |
| 31 | Toolchest Provider of an API for data analytics | $125K | 46 mo ago | 3 | Bryce Cai Co-Founder & CTO | Deadpooled | — | — |
| 32 | Targagenix Developer of novel compounds intended to treat drug-resistant tumors and cancer stem cells | $100K | 93 mo ago | 8 | — | Seed | 20 patents Nanoemulsion-based taxoid drug delivery systems combined with cancer immunotherapy | — |
Top 12 Life Sciences companies in Wilmington
#1
Series A · Wilmington, Delaware · founded 2014 · 4 employees$6.5Mraised▾
Provider of mobile isolation units for infection control in hospitals. It offers medical-grade isolation technology-based negative-pressure isolation unit which has two lean-in glove walls, hugsuit, and others. It allow care givers to isolate patients and prevent the spread of infectious diseases.
- Mar 2026Series A$6.5M
#2
Series A · Wilmington, Delaware · founded 2024$30.5Mraised▾
Developer of GenAI computational tools for drug discovery and manufacturing. The company offers a bio-LLM library with foundation models across biological languages. These models are enhanced with curated data and fine-tuned on task-specific datasets. The platform is deployed through an application layer focused on prediction, explainability, and generation. It provides AI-driven antibody discovery and optimization, protein yield maximization, and cellular response prediction. The platform ensures data privacy and security, offering complete control and fully managed infrastructure.
- Sep 2025Series A$25M
- Nov 2024Seed$5.5M
#3
Series B · Wilmington, Massachusetts · founded 2014 · 13 employees$13Mraised▾
Developer of a device for CLI and PAD patients to prevent amputation. The company develops minimally invasive tools for microvascular intervention. The company's products MicroStent, a vascular stent specifically designed to reduce below-the-knee amputations for critical limb ischemia (CLI) resulting from peripheral artery disease.
- Oct 2025Series B$2.3M
- Jul 2025Series B$2.5M
- Oct 2022Conventional Debt$2.2M
- Oct 2021Conventional Debt$1.3M
#4
Public · Wilmington, Delaware · founded 2008 · 23 employees$18.5Mraised▾
Developer of biologics products by using transient gene expression. It develops and offers product applications of its iBioLaunch and iBioModulator platforms for proprietary and biosimilar products. The iBioLaunch platform is a proprietary technology for the development and production of biologics using transient gene expression in unmodified green plants. The offering applies to biologics, including monoclonal antibodies, other therapeutic proteins, and vaccines, optionally robotic, multi-product manufacturing facilities.
- Apr 2025Post IPO$6.2M
- Mar 2020Post IPO—
- Feb 2016Post IPO$2.2M
- Nov 2010Post IPO$7.1M
#5
Series A · Wilmington, Delaware · founded 2013 · 30 employees$6.5Mraised▾
Provider of solutions for managing manufacturing operations in manufacturing industries
- Aug 2025Series A$6.1M
- Oct 2019Series A$6M
- Dec 2017Seed—
- Jul 2014Seed$550K
#6
Seed · Wilmington, Delaware · founded 2021$500Kraised▾
AI-based software for cell and gene therapy. The company is pioneering mechanistic AI to revolutionize cell and gene therapy manufacturing to make life saving therapies.
- Jun 2025Seed$500K
#7
Seed · Wilmington, Delaware · founded 2013 · 6 employees$3.9Mraised▾
Provider of cloud-based electronic laboratory log management platform. The company has developed a lab records and tasks maintenance software that allows users to report, and track records. The system has features for tracking tasks of different research instruments, get real-time data, and more.
- Jul 2024Seed$1.8M
- Mar 2024Seed$1.8M
- Oct 2021Seed$326.6K
#8
Funding Raised · Wilmington, Delaware · founded 2022$693.4Kraised▾
Developer of medical devices for thrombectomy procedures. The company offers ALGO Smart Pump that uses smart static aspiration technology to improve the precision and effectiveness of clot retrieval in stroke treatment.
- Apr 2025Grant (prize money)$693.4K
#9
Series C · Wilmington, Delaware · founded 2017 · 24 employees$260Mraised▾
Developer of therapeutics for the treatment of cancer. The company focused on developing innovative small molecule oncology medicines to bring transformative therapies to patients. The company's product line include NKT5097 is an orally bioavailable small molecule designed to selectively degrade CDK2 and CDK4 simultaneously, offering potential therapeutic benefits for patients with HR+ breast cancer and cancers with aberrant CDK2/cyclin E pathway activation.
- May 2021Series C$200M
- Sep 2020Series B$50M
- 2017Series A$10M
#10
Public · Wilmington, Delaware · founded 1991 · 1387 employees$750Mraised▾
Developer of small molecules for the treatment of different cancer and skin diseases. The company provides Jakafi to treat polycythemia vera (PV) and myelofibrosis (MF). Its product pipeline includes Pemazyre for Cholangiocarcinoma3 Monjuv for lymphoma, Iclusig for chronic myeloid leukemia, ruxolitinib for chronic GVHD, and others.
- Nov 2013Post IPO$750M
#11
Funding Raised · Wilmington, Delaware · founded 2022$600Kraised▾
Developer of immunotherapeutics to treat allergic diseases. The company is developing novel CAR T cells that target and eliminate the source of allergic disease specifically targeting uncontrollable severe allergic asthma and severe food allergy.
- Jan 2025Grant (prize money)$300K
- Jan 2024Grant (prize money)$300K
#12
NRx 🦄Public · Wilmington, Delaware · founded 2017 · 22 employees$55.3Mraised▾
Developer of therapeutics for COVID-19 and neurological disorders. The company's product include ZYESAMI contains aviptadil acetate for COVID-19 with respiratory failure, NRX-101, and NRX-100 for the treatment of acute suicidal behavior in bipolar disorder.
- Feb 2022Post IPO$25M
- Aug 2021Post IPO$30M
- Feb 2017Grant (prize money)$343K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Where biotechnology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in the United States
United States biotechnology patent filing is accelerating — 457,918 filings from 8,000 assignees (2016–2025), led by Genentech, UNIV California, Regeneron Pharma; annual filings 36884→44446.
- Genentech18078
- UNIV California17948
- Regeneron Pharma16082
- Amgen10495
- Monsanto Technology9742
- UNIV Pennsylvania8521
- Harvard College7460
- UNIV Texas7378
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.